Authors: Arnold Bolomsky, Juho J. Miettinen, Alina Malyutina, Andrej Besse, Julia Huber, Stefanie Fellinger, Helene Breid, Alun Parsons, Kristaps Klavins, J. Thomas Hannich, Stefan Kubicek, Jo Caers, Wolfgang Hübl, Martin Schreder, Niklas Zojer, Christoph Driessen, Jing Tang, Lenka Besse, Caroline A. Heckman, Heinz Ludwig

Source: Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Advances, 5(20), 4125-4139., United States. (2021).

Subject Terms: Hematology, Cell Line, Tumor, Family, Humans, Multiple Myeloma/drug therapy, Myeloid Cell Leukemia Sequence 1 Protein/genetics, Pharmaceutical Preparations, bcl-X Protein, Hematology [Human health sciences], Hématologie [Sciences de la santé humaine]

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a4ea478f3f22662a9e88648ef15da78
http://ashpublications.org/bloodadvances/article-pdf/5/20/4125/1828967/advancesadv2020003826.pdf

Authors: Karen Louise Højholt, Henrik Gregersen, Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen, Annette Juul Vangsted

Source: Højholt, K L, Gregersen, H, Szabo, A G, Klausen, T W, Levring, M B, Preiss, B, Helleberg, C, Breinholt, M F, Hermansen, E, Rahbek Gjerdrum, L M, Bønløkke, S T, Nielsen, K, Kjeldsen, E, Iversen, K F, Teodorescu, E M, Kurt, E, Strandholdt, C, Andersen, M K & Vangsted, A J 2021, ' Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients ', Hematological Oncology, vol. 39, no. 4, pp. 521-528 . https://doi.org/10.1002/hon.2906

Subject Terms: carfilzomib, daratumumab, multiple myeloma, real-world evidence, Cancer Research, Oncology, Hematology, General Medicine, Humans, Middle Aged, Neoplasm Recurrence, Local, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Oligopeptides/pharmacology, Aged, Retrospective Studies, Multiple Myeloma/drug therapy, Antibodies, Monoclonal/pharmacology

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61024888296e62b7a6177aeb85a53828
https://vbn.aau.dk/da/publications/b5981f72-cfb0-4ed2-84e7-94d0da586440

Authors: Daniela Niepel, Anouchka Seesaghur, Anne Gulbech Ording, Ina Trolle Andersen, Niels Abildgaard, Trine Silkjaer, Carsten Helleberg, Vera Ehrenstein, Rohini K. Hernandez, Tina Bech Olesen

Source: Olesen, T B, Andersen, I T, Ording, A G, Ehrenstein, V, Seesaghur, A, Helleberg, C, Silkjær, T, Hernandez, R K, Niepel, D & Abildgaard, N 2021, ' Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015 ', Supportive Care in Cancer, vol. 29, no. 8, pp. 4501-4511 . https://doi.org/10.1007/s00520-020-05934-8

Subject Terms: Bisphosphonates, Epidemiology, Multiple myeloma, Severity of Illness Index, Humans, Middle Aged, Male, Bone Density Conservation Agents/therapeutic use, Disease Progression, Diphosphonates/therapeutic use, Denmark, Female, Registries, Aged, Kidney Diseases/chemically induced, Multiple Myeloma/drug therapy, Bone Neoplasms/drug therapy, Cohort Studies, Oncology, Medicine, business.industry, business, medicine.disease, Disease progression, Quartile, Internal medicine, medicine.medical_specialty, Population, education.field_of_study, education, Cohort study, First line, Bone disease, hemic and lymphatic diseases

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2b5619c16c21ed7a504020d902ad7f
https://portal.findresearcher.sdu.dk/da/publications/a37e5f70-80fa-480c-90e8-cb6078084e52

Authors: Braham, Maaike V.J., Deshantri, Anil K., Minnema, Monique C., Öner, F. Cumhur, Schiffelers, Raymond M., Fens, Marcel H.A.M., Alblas, Jacqueline

Source: International Journal of Nanomedicine
Journal of Nanomedicine, 13, 8105. Dove Medical Press Ltd.
International Journal of Nanomedicine, 13, 8105
International Journal of Nanomedicine, Vol Volume 13, Pp 8105-8118 (2018)

Subject Terms: Original Research, liposomes, targeted delivery, tumor microenvironment, drug sensitivity and resistance testing, multiple myeloma, Journal Article, Antibiotics, Antineoplastic/administration & dosage, Bone Marrow/drug effects, Cell Proliferation, Doxorubicin/administration & dosage, Drug Delivery Systems, Humans, In Vitro Techniques, Liposomes/administration & dosage, Models, Biological, Multiple Myeloma/drug therapy, Tumor Cells, Cultured, drug delivery, lcsh:Medicine (General), lcsh:R5-920, International Journal of Nanomedicine, Organic Chemistry, Drug Discovery, General Medicine, Biomaterials, Bioengineering, Biophysics, Pharmaceutical Science, Doxorubicin, medicine.drug, medicine, Multiple myeloma, medicine.disease, Bone marrow, medicine.anatomical_structure, Therapeutic index, Cancer research, business.industry, business, Bortezomib, Drug delivery, Liposome, Progenitor cell, Antibiotics, Antineoplastic/administration & dosage, Models, Biological, Tumor Cells, Cultured

File Description: image/pdf; text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a23097e98fb241488e1aedcc5b81ba
http://europepmc.org/articles/PMC6278842

Authors: Inger S. Nijhof, Jakub Krejcik, Torben Plesner, Berris van Kessel, A. Kate Sasser, René J. P. Musters, Niels W.C.J. van de Donk, Richard W.J. Groen, Marloes E.C. Broekmans, Tuna Mutis, Jeroen F. van Velzen, Kris A. Frerichs, Johan van Meerloo, Andries C. Bloem, Christopher Chiu, Henk M. Lokhorst, Pino J. Poddighe, Sonja Zweegman

Contributors: Hematology laboratory, Hematology, CCA - Cancer biology and immunology, AII - Cancer immunology, Physiology, Clinical genetics

Source: Krejcik, J, Frerichs, K A, Nijhof, I S, van Kessel, B, van Velzen, J, Bloem, A C, Broekmans, M, Zweegman, S, van Meerloo, J, Musters, R J, Poddighe, P, Groen, R, Chiu, C, Plesner, T, Lokhorst, H M, Sasser, A K, Mutis, T & van de Donk, N W C J 2017, ' Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab ', Clinical Cancer Research, vol. 23, no. 24, pp. 7498-7511 . https://doi.org/10.1158/1078-0432.CCR-17-2027
Clinical Cancer Research, 23(24), 7498-7511. American Association for Cancer Research Inc.

Subject Terms: Cancer Research, Oncology, Trogocytosis, Immunology, Immune system, CD38, Biology, Daratumumab, Multiple myeloma, medicine.disease, medicine, Lenalidomide, medicine.drug, Antibody, biology.protein, Cell culture, ADP-ribosyl Cyclase 1/genetics, Aged, Antibodies, Monoclonal/administration & dosage, B-Lymphocytes/immunology, Cell Line, Tumor, Dexamethasone/administration & dosage, Female, Gene Expression Regulation, Neoplastic/drug effects, Granulocytes/drug effects, Humans, Killer Cells, Natural/immunology, Male, Middle Aged, Monocytes/drug effects, Multiple Myeloma/drug therapy, T-Lymphocytes, Thalidomide/administration & dosage, Journal Article, Article, hemic and lymphatic diseases, immune system diseases

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a411b4972ab21d4db661d3cca064dd68
https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-17-2027

Authors: Spicka, Ivan, Ocio, Enrique María, Oakervee, Heather H.E., Greil, Richard, Banh, Raymond H, Huang, Shang Yi, D'Rozario, James M, Dimopoulos, Meletios Athanassios, Martínez, Sara, Extremera, Sonia, Kahatt, Carmen, Alfaro, Vicente, Carella, Angelo Michele, Meuleman, Nathalie, Hájek, Roman, Symeonidis, Argiris, Min, Chang Ki, Cannell, Paul, Ludwig, Heinz, Sonneveld, Pieter, Mateos, Maria-Victoria

Contributors: Department of Hematology

Source: Annals of Hematology, 98(9), 2139-2150
Annals of hematology
Annals of Hematology
Annals of hematology, 98 (9

Subject Terms: Multiple myeloma . Plitidepsin . Dexamethasone . Relapsed . Refractory, Hématologie, Dexamethasone, Multiple myeloma, Plitidepsin, Refractory, Relapsed, Original Article, Hematology, General Medicine, Bortezomib, medicine.drug, medicine, Internal medicine, medicine.medical_specialty, Nausea, medicine.symptom, medicine.disease, Lenalidomide, Thalidomide, business.industry, business, Gastroenterology, Clinical endpoint, Sciences bio-médicales et agricoles, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage, Bortezomib -- administration & dosage, Depsipeptides -- administration & dosage, Dexamethasone -- administration & dosage, Disease-Free Survival, Female, Humans, Lenalidomide -- administration & dosage, Male, Middle Aged, Multiple Myeloma -- drug therapy -- mortality, Survival Rate, Thalidomide -- administration & dosage

File Description: application/pdf; 1 full-text file(s): application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bca21caae1db2c673a339baafea4841c
http://hdl.handle.net/1765/121027

Authors: Facon, T., Kumar, Shaji, Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Rampelbergh, R. Van, Uhlar, C. M., Kobos, R., Qi, M., Usmani, S. Z., Abildgaard, Niels

Source: Facon, T, Kumar, S, Plesner, T, Orlowski, R Z, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O’Dwyer, M, Perrot, A, Venner, C P, Weisel, K, Mace, J R, Raje, N, Attal, M, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Chiu, C, Wang, J, Rampelbergh, R V, Uhlar, C M, Kobos, R, Qi, M, Usmani, S Z, MAIA Trial Investigators & Abildgaard, N 2019, ' Daratumumab plus lenalidomide and dexamethasone for untreated Myeloma ', New England Journal of Medicine, vol. 380, no. 22, pp. 2104-2115 . https://doi.org/10.1056/NEJMoa1817249

Subject Terms: Aged, Aged, 80 and over, Antibodies, Monoclonal/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Dexamethasone/administration & dosage, Female, Humans, Lenalidomide/administration & dosage, Male, Middle Aged, Multiple Myeloma/drug therapy, Neutropenia/chemically induced, Progression-Free Survival, General Medicine, Medicine, business.industry, business, Oncology, medicine.medical_specialty, Bortezomib, medicine.drug, Daratumumab, Multiple myeloma, medicine.disease, Standard treatment, Transplantation, Dexamethasone, Internal medicine, Lenalidomide, Isatuximab

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3ab3633dfb860f2b0cd95f9e39f460d
https://findresearcher.sdu.dk:8443/ws/files/157632593/nejmoa1817249.pdf

Authors: Nielsen, Lene Kongsgaard, Abildgaard, Niels, Jarden, Mary, Klausen, Tobias Wirenfeld

Source: Nielsen, L K, Abildgaard, N, Jarden, M & Klausen, T W 2019, ' Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma ', British Journal of Haematology, vol. 185, no. 1, pp. 11-24 . https://doi.org/10.1111/bjh.15759
Kongsgaard Nielsen, L, Abildgaard, N, Jarden, M E & Klausen, T W 2019, ' Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma ', British Journal of Haematology, vol. 185, no. 1, pp. 11-24 . https://doi.org/10.1111/bjh.15759

Subject Terms: health-related quality of life, missing data, multiple myeloma, review, statistical analysis, Hematology, Daily practice, Quality of life, In patient, Gerontology, Medicine, business.industry, business, Multiple myeloma, medicine.disease, Missing data, Health related quality of life, Data collection, Disease, Datasets as Topic, Attitude to Health, Humans, Treatment Outcome, Multicenter Studies as Topic/statistics & numerical data, Clinical Trials as Topic/statistics & numerical data, Patient Acceptance of Health Care, Quality of Life, Surveys and Questionnaires, Multiple Myeloma/drug therapy, Patient Reported Outcome Measures, humanities

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cecf6b0da1ed4c3816d5869fe2d9bbe4
https://curis.ku.dk/portal/da/publications/methodological-aspects-of-healthrelated-quality-of-life-measurement-and-analysis-in-patients-with-multiple-myeloma(ebf1929e-6f00-4099-b4db-33d70b59ce52).html

Authors: Dimopoulos, Meletios A, Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria-Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B, Gupta, Neeraj, Labotka, Richard, Rajkumar, S Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araújo, Sérgio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Röllig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illés, Árpád, Egyed, Miklós, Borbényi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukås, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Álvarez Rivas, Miguel Angel, De Arriba de La Fuente, Felipe, González Montes, Yolanda, Martin Sanchez, Jesus, Mateos, Maria Victoria, Oriol Rocafiguera, Albert, Rosinol, Laura, San Miguel, Jesús, Pérez de Oteyza, Jaime, Encinas, Cristina, Alegre-Amor, Adrian, López-Guía, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Hveding Blimark, Cecile, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Na Nakorn, Thanyaphong, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali

Contributors: Takeda Pharmaceutical Company, CCA - Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, Hematology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL)

Source: Lancet, 393(10168), 253. Elsevier Limited
The Lancet, 393(10168), 253-264. Elsevier Limited
Dimopoulos, M A, Gay, F, Schjesvold, F, Beksac, M, Hajek, R, Weisel, K C, Goldschmidt, H, Maisnar, V, Moreau, P, Min, C K, Pluta, A, Chng, W-J, Kaiser, M, Zweegman, S, Mateos, M-V, Spencer, A, Iida, S, Morgan, G, Suryanarayan, K, Teng, Z, Skacel, T, Palumbo, A, Dash, A B, Gupta, N, Labotka, R, Rajkumar, S V, Abildgaard, N & TOURMALINE-MM3 study group 2019, ' Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 253-264 . https://doi.org/10.1016/S0140-6736(18)33003-4
LANCET, 393(10168), 253-264. ELSEVIER SCIENCE INC

Subject Terms: General Medicine, Maintenance therapy, Autologous stem-cell transplantation, Clinical trial, Internal medicine, medicine.medical_specialty, medicine, Regimen, business.industry, business, Ixazomib, chemistry.chemical_compound, chemistry, Transplantation, Clinical endpoint, Placebo, Administration, Oral, Antineoplastic Agents/administration & dosage, Boron Compounds/administration & dosage, Disease Progression, Double-Blind Method, Female, Glycine/administration & dosage, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Stem Cell Transplantation, Time Factors, Transplantation, Autologous, Treatment Outcome, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Medicine(all), Administration, Oral, Autologous, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, DIAGNOSED MULTIPLE-MYELOMA, HIGH-DOSE THERAPY, LENALIDOMIDE MAINTENANCE, IMPROVES SURVIVAL, BORTEZOMIB, DEXAMETHASONE, CHEMOTHERAPY, THALIDOMIDE, INDUCTION

File Description: image/pdf; application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de353f2eca3bce4266841424f74a30c

Authors: Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A. Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

Contributors: Hematology, CCA - Clinical Therapy Development

Source: Usmani, S Z, Weiss, B M, Plesner, T, Bahlis, N J, Belch, A, Lonial, S, Lokhorst, H M, Voorhees, P M, Richardson, P G, Chari, A, Sasser, A K, Axel, A, Feng, H, Uhlar, C M, Wang, J, Khan, I, Ahmadi, T & Nahi, H 2016, ' Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma ', Blood, vol. 128, no. 1, pp. 37-44 . https://doi.org/10.1182/blood-2016-03-705210
Blood, 128(1), 37-44. American Society of Hematology

Subject Terms: Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Recurrence, Remission Induction, Survival Rate, Cell Biology, Hematology, Immunology, Biochemistry, Phases of clinical research, Medicine, business.industry, business, Surgery, medicine.medical_specialty, Gastroenterology, Internal medicine, Survival rate, Refractory, Daratumumab, Absolute neutrophil count, Confidence interval, Population, education.field_of_study, education, Progressive disease, medicine.disease, Clinical Trials and Observations

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f295fc13f374ff3f19aa41f321afe70c

Authors: Philippe Moreau, Torben Plesner, Jesús F. San Miguel, Dina Ben-Yehuda, Pieter Sonneveld, Meletios A. Dimopoulos, Pia Sondergeld, Gordon Cook, Henk M. Lokhorst, Thierry Facon, Michele Cavo, Sonja Zweegman, Michel Delforge, Christoph Driessen, Hermann Einsele, Maria-Victoria Mateos, Hareth Nahi, Niels W.C.J. van de Donk, Antonio Palumbo, Heinz Ludwig

Contributors: Hematology, CCA - Clinical Therapy Development

Source: Drugs, 76(8), 853-867. Adis International Ltd
Moreau, P, van de Donk, N W C J, San Miguel, J, Lokhorst, H, Nahi, H, Ben-Yehuda, D, Cavo, M, Cook, G, Delforge, M, Einsele, H, Zweegman, S, Ludwig, H, Driessen, C, Palumbo, A, Facon, T, Plesner, T, Dimopoulos, M, Sondergeld, P, Sonneveld, P & Mateos, M-V 2016, ' Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma ', Drugs, vol. 76, no. 8, pp. 853-867 . https://doi.org/10.1007/s40265-016-0573-4

Subject Terms: Pharmacology (medical), Immunotherapy, medicine.medical_treatment, medicine, business.industry, business, Monoclonal antibody, medicine.drug_class, Clinical trial, Tolerability, Pharmacotherapy, CD38, Daratumumab, Multiple myeloma, medicine.disease, Immunology, Monoclonal antibodies (mAbs), multiple myeloma, ADP-ribosyl Cyclase 1/immunology, Antibodies, Monoclonal/administration & dosage, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Clinical Trials as Topic, Humans, Infusions, Intravenous, Multiple Myeloma/drug therapy

File Description: STAMPA

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::140b4ed476b5cf90b9fbd3cddfe22c43

Authors: Ben Bakrim, Widad, El Bouzidi, Laila, Nuzillard, Jean-Marc, Cretton, Sylvian, Saraux, Noémie, Monteillier, Aymeric, Christen, Philippe, Cuendet, Muriel, Bekkouche, Khalid

Contributors: Université Cadi Ayyad [Marrakech] (UCA), Chimie des Substances Naturelles (ICMRCSN), Institut de Chimie Moléculaire de Reims - UMR 7312 (ICMR), Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-SFR Condorcet, Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS), University of Geneva [Switzerland]

Source: Pharmaceutical Biology
Pharmaceutical Biology, Taylor & Francis, 2018, 56 (1), pp.505-510. ⟨10.1080/13880209.2018.1499781⟩
Pharmaceutical Biology, Vol 56, Iss 1, Pp 505-510 (2018)
Pharmaceutical Biology, Vol. 56, No 1 (2018) pp. 505-510

Subject Terms: antiproliferative activity, Withanolides, wadpressine, antioxidant activity, NF-κB inhibition, [CHIM.THER]Chemical Sciences/Medicinal Chemistry, [SDV.BV.BOT]Life Sciences [q-bio]/Vegetal Biology/Botanics, Research Article, lcsh:Therapeutics. Pharmacology, lcsh:RM1-950, ddc:615, Antioxidants/chemistry/isolation & purification/pharmacology, Cell Proliferation/drug effects, Flavonoids/chemistry/isolation & purification/pharmacology, HEK293 Cells, Humans, Multiple Myeloma/drug therapy, NF-kappa B/antagonists & inhibitors, Phenols/chemistry/isolation & purification/pharmacology, Plant Extracts/chemistry/isolation & purification/pharmacology, Plant Leaves/chemistry, Withania/chemistry, Withanolides/chemistry/isolation & purification/pharmacology

Access URL: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::47dbc224e1574ccb93eb9311ab1fa5e9
https://hal.univ-reims.fr/hal-01992872

Authors: Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, Richardson, Paul G

Contributors: Hematology, CCA - Clinical Therapy Development

Source: Plesner, T, Arkenau, H-T, Gimsing, P, Krejcik, J, Lemech, C, Minnema, M C, Lassen, U, Laubach, J P, Palumbo, A, Lisby, S, Basse, L, Wang, J, Sasser, A K, Guckert, M E, de Boer, C, Khokhar, N Z, Yeh, H, Clemens, P L, Ahmadi, T, Lokhorst, H M & Richardson, P G 2016, ' Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma ', Blood, vol. 128, no. 14, pp. 1821-1828 . https://doi.org/10.1182/blood-2016-07-726729
Blood, 128(14), 1821-1828. American Society of Hematology
Blood, 128(14), 1821. American Society of Hematology

Subject Terms: Aged, Antibodies, Monoclonal/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Demography, Dexamethasone/adverse effects, Disease-Free Survival, Female, Humans, Lenalidomide, Middle Aged, Multiple Myeloma/drug therapy, Recurrence, Thalidomide/adverse effects, Treatment Outcome, Cell Biology, Hematology, Immunology, Biochemistry, Internal medicine, medicine.medical_specialty, medicine, Autologous stem-cell transplantation, Daratumumab, Multiple myeloma, medicine.disease, business.industry, business, Refractory, Dexamethasone, medicine.drug, Thalidomide, Pharmacology, Neutropenia, Gastroenterology, Clinical Trials and Observations, Journal Article

File Description: image/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af588d173f91d363cd957f3c2d392ad
https://portal.findresearcher.sdu.dk/da/publications/169a6a58-7cc8-4fc9-8f16-85817a49f7ae

Authors: Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z., O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Source: Dimopoulos, M A, Oriol, A, Nahi, H, San-Miguel, J, Bahlis, N J, Usmani, S Z, Rabin, N, Orlowski, R Z, Komarnicki, M, Suzuki, K, Plesner, T, Yoon, S-S, Ben Yehuda, D, Richardson, P G, Goldschmidt, H, Reece, D, Lisby, S, Khokhar, N Z, O'Rourke, L, Chiu, C, Qin, X, Guckert, M, Ahmadi, T, Moreau, P & POLLUX Investigators 2016, ' Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma ', The New England Journal of Medicine, vol. 375, no. 14, pp. 1319-1331 . https://doi.org/10.1056/NEJMoa1607751

Subject Terms: Aged, Antibodies, Monoclonal/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Dexamethasone/administration & dosage, Disease-Free Survival, Drug Resistance, Neoplasm, Humans, Kaplan-Meier Estimate, Lenalidomide, Middle Aged, Multiple Myeloma/drug therapy, Recurrence, Thalidomide/administration & dosage, General Medicine, Elotuzumab, medicine.drug, medicine, Internal medicine, medicine.medical_specialty, Hazard ratio, Oncology, Ixazomib, chemistry.chemical_compound, chemistry, business.industry, business, Surgery, Interim analysis, Daratumumab, Multiple myeloma, medicine.disease, Dexamethasone

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61628e9bf3047e8da229f84c6cb1962
https://findresearcher.sdu.dk:8443/ws/files/128446815/Daratumumab_Lenalidomide_and_Dexamethasone_for_Multiple_Myeloma.pdf

Authors: Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., Van De Donk, N. W C J, Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N., Richardson, P. G.

Contributors: Hematology, Hematology laboratory, CCA - Innovative therapy

Source: New England Journal of Medicine, 373(13), 1207-1219. Massachussetts Medical Society
Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', The New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348
New England Journal of Medicine, 373(13), 1207. Massachussetts Medical Society

Subject Terms: General Medicine, Lenalidomide, medicine.drug, medicine, Bortezomib, Refractory, Isatuximab, Adverse effect, Daratumumab, Multiple myeloma, medicine.disease, Surgery, medicine.medical_specialty, business.industry, business, Elotuzumab, Gastroenterology, Internal medicine, Medicine(all), Clinical Trial, Phase I, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, MONOCLONAL-ANTIBODY ANTITUMOR-ACTIVITY MULTICENTER BORTEZOMIB ELOTUZUMAB SAR650984 THERAPIES SURVIVAL PROTEIN CELLS, ADP-ribosyl Cyclase 1/antagonists & inhibitors, Adult, Aged, Antibodies, Monoclonal/administration & dosage, Antineoplastic Agents/administration & dosage, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Female, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Pneumonia/chemically induced, Thrombocytopenia/chemically induced, Clinical Trial, Phase I, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't

File Description: image/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b091a32c87a186a362edd84a61a4d327

Authors: Richard W.J. Groen, Anton C.M. Martens, Kelly van den Oudenalder, Tuna Mutis, Andries C. Bloem, Robbert M. Spaapen, Tineke Aarts-Riemens, Teun Guichelaar, Gert Storm, Maureen van Elk, Henk M. Lokhorst

Contributors: Hematology laboratory, Hematology

Source: Clinical Cancer Research, 16(22), 5481-8. American Association for Cancer Research Inc.

Subject Terms: Cancer Research, Oncology, Bone marrow, medicine.anatomical_structure, medicine, Cytotoxic T cell, Antigen, Major histocompatibility complex, biology.protein, biology, Immunotherapy, medicine.medical_treatment, Minor histocompatibility antigen, Immunology, Antigen-presenting cell, T lymphocyte, Animals, CD4-Positive T-Lymphocytes/immunology, DNA-Binding Proteins/deficiency, Humans, Mice, Minor Histocompatibility Antigens/administration & dosage, Multiple Myeloma/drug therapy, Receptors, T-Cell/administration & dosage, Receptors, Antigen, T-Cell/administration & dosage

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505455e3a9cb5f9ccd0a9c0c346dadce
https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-10-1340

Authors: Alexandre Christinat, Serge Leyvraz

Source: OncoTargets and therapy
OncoTargets and Therapy, Vol 2009, Iss default, Pp 105-113 (2009)
Oncotargets and Therapy, vol. 2, no. 9, pp. 105-113

Subject Terms: Review, soft tissue sarcoma, trabectedin, chemotherapy, DNA-minor groove binder, OncoTargets and Therapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Pharmacology (medical), Oncology, Premedication, medicine.medical_specialty, medicine, Trabectedin, medicine.drug, Chemotherapy, medicine.medical_treatment, Ecteinascidia turbinata, biology.organism_classification, biology, Pathology, Soft tissue sarcoma, medicine.disease, business.industry, business, Internal medicine, Cell culture, Dexamethasone, Liver function tests, medicine.diagnostic_test, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Cytarabine/administration & dosage, Dexamethasone/administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Genetic Heterogeneity, Hemoglobins, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Multiple Myeloma/genetics, Multivariate Analysis, Prognosis, Retrospective Studies, Translocation, Genetic, Vincristine/administration & dosage, beta 2-Microglobulin/blood

File Description: text/html; application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4458d7fb32f38b04f90ab4763af916bc
http://europepmc.org/articles/PMC2886331

Authors: Charlotte Toftmann Hansen, Jean-Marie Delaissé, Erik Jakobsen, Torben Plesner, Kent Søe

Source: Søe, K, Delaissé, J-M, Jakobsen, E H, Hansen, C & Plesner, T 2014, ' Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer ', Acta Oncologica, vol. 53, no. 4, pp. 547-556 . https://doi.org/10.3109/0284186X.2013.844358

Subject Terms: Adult, Biomarkers, Tumor/analysis, Bone Density Conservation Agents/therapeutic use, Bone Neoplasms/drug therapy, Breast Neoplasms/drug therapy, Creatinine/urine, Diphosphonates/therapeutic use, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Imidazoles/therapeutic use, Male, Middle Aged, Multiple Myeloma/drug therapy, Neoplasm Staging, Prognosis, Prospective Studies, Radioimmunoassay, Zoledronic Acid, Radiology Nuclear Medicine and imaging, Oncology, Hematology, General Medicine, Bone disease, medicine.disease, medicine, Pathology, medicine.medical_specialty, business.industry, business, Bisphosphonate, medicine.medical_treatment, Zoledronic acid, medicine.drug, Urology, Metastasis, Breast cancer, Metastatic breast cancer, Renal function, Multiple myeloma

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::807a3860da813696b8c4845c80cc1c2d
https://portal.findresearcher.sdu.dk/da/publications/f096502a-745a-4d35-b443-0485165d2d76

Authors: Ismail Sari, Ali Keskin, Mehmet Hilmi Dogu, Sibel Hacioglu

Subject Terms: Cyclophosphamide, Granulocyte colony stimulating factor, Multiple myeloma, Stem cell mobilization, antineoplastic agent, mesna, recombinant granulocyte colony stimulating factor, CD34 antigen, recombinant protein, adult, aged, apheresis, article, cancer chemotherapy, cancer radiotherapy, chronotherapy, clinical article, drug dose increase, female, hemorrhagic cystitis, human, male, middle aged, peripheral blood stem cell, retrospective study, cost benefit analysis, economics, metabolism, procedures, time, Antigens, CD34, Blood Component Removal, Cost-Benefit Analysis, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Humans, Recombinant Proteins, Retrospective Studies, Time Factors, Adult, Aged, Antigens, CD34/metabolism, Cyclophosphamide/*therapeutic use, Female, Granulocyte Colony-Stimulating Factor/economics/*therapeutic use, Hematopoietic Stem Cell Mobilization/economics/*methods, Male, Middle Aged, Multiple Myeloma/*drug therapy/therapy, Recombinant Proteins/therapeutic use, Hematology, Stem cell, Urology, medicine.medical_specialty, medicine, Mobilization, Surgery, Regimen, business.industry, business, medicine.drug, Granulocyte colony-stimulating factor, CD34, medicine.disease, In patient

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5b9ef22caa7525698f81657877512a
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/7577

Authors: Ulrich Mey, Dominik Heim, Michael Gregor, J. Gmur, Nicolas Ketterer, Christian Taverna, Mario Bargetzi, Thomas Pabst, Thomas Matthes, Daniel Betticher, Christoph Renner, Urs Hess, Erika Lerch

Source: Swiss Medical Weekly, vol. 140, pp. w13054
Schweizerische medizinische Wochenschrift, Vol. 140 (2010) P. w13054

Subject Terms: Aged, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Biopsy, Needle, Bone Marrow/drug effects, Bone Marrow/pathology, Bone Marrow Transplantation, Boronic Acids/adverse effects, Boronic Acids/therapeutic use, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Evidence-Based Medicine, Humans, Middle Aged, Multiple Myeloma/diagnosis, Multiple Myeloma/drug therapy, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Plasma Cells/drug effects, Plasma Cells/pathology, Pyrazines/adverse effects, Pyrazines/therapeutic use, Retreatment, Switzerland%22">Type="Geographic">Switzerland, Thalidomide/adverse effects, Thalidomide/analogs & derivatives, General Medicine, Clinical Practice, Multiple myeloma, medicine.disease, medicine, Evidence-based medicine, Bortezomib, medicine.drug, business.industry, business, Intensive care medicine, medicine.medical_specialty, Novel agents, Lenalidomide, Surgery, Thalidomide, ddc:500.2, ddc:616, Antineoplastic Agents/adverse effects/*therapeutic use, Bone Marrow/drug effects/pathology, Boronic Acids/adverse effects/therapeutic use, Multiple Myeloma/diagnosis/*drug therapy/pathology, Neoplasm Recurrence, Local/drug therapy/pathology, Plasma Cells/drug effects/pathology, Pyrazines/adverse effects/therapeutic use, Switzerland, Thalidomide/adverse effects/analogs & derivatives/therapeutic use

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be3c15e558142e42c798fc3542028e5
https://serval.unil.ch/resource/serval:BIB_8873EB254E5F.P001/REF.pdf